Get started
Author

Claudia Wagner

Observed names: Claudia S Wagner, Claudia S. Wagner
Observed institutions: Karolinska University Hospital, Howard Hughes Medical Institute, Karolinska Institutet, Yale University, Universitätsklinikum des Saarlandes, Immatics Biotechnologies (Germany), University of Tübingen, Saarland University
ORCID: 0000-0002-7311-2236
Observed ORCID: 0000-0002-7311-2236
OpenAlex ID: A5073053476
Actively personalized vaccination trial for newly diagnosed glioblastoma
2018 · Norbert Hilf, Sabrina Kuttruff-Coqui, et al. · Nature · 948
Consequences of Membrane Protein Overexpression in Escherichia coli
2007 · Samuel Wagner, Louise Baars, et al. · Molecular & Cellular Proteomics · 398
PDF
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
2016 · Brian I Rini, Arnulf Stenzl, et al. · The Lancet Oncology · 228
Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial
2025 · Martin Wermke, Dejka M. Araujo, et al. · Nature Medicine · 78
Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer.
2006 · Boris Kubuschok, Frank Neumann, et al. · Clinical Cancer Research · 58
Human cytomegalovirus-derived protein UL18 alters the phenotype and function of monocyte-derived dendritic cells
2007 · Claudia S Wagner, Lilian Walther-Jallow, et al. · Journal of Leukocyte Biology · 46
TLR and Nucleotide-Binding Oligomerization Domain-like Receptor Signals Differentially Regulate Exogenous Antigen Presentation
2011 · Claudia S Wagner, Peter Cresswell · The Journal of Immunology · 42
Quantitative immunopeptidomics reveals a tumor stroma–specific target for T cell therapy
2022 · Gloria B. Kim, Jens Fritsche, et al. · Science Translational Medicine · 41
PDF
Increased Expression of Leukocyte Ig-Like Receptor-1 and Activating Role of UL18 in the Response to Cytomegalovirus Infection
2007 · Claudia S Wagner, Gerdt C Riise, et al. · The Journal of Immunology · 41
High-throughput peptide-MHC complex generation and kinetic screenings of TCRs with peptide-receptive HLA-A*02:01 molecules
2019 · Andreas Moritz, Raghavendra Anjanappa, et al. · Science Immunology · 39
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors
2024 · Martin Wermke, Tobias A W Holderried, et al. · Journal for ImmunoTherapy of Cancer · 35
Intracellular events regulating cross-presentation
2012 · Claudia S. Wagner, Jeffrey E. Grotzke, et al. · Frontiers in Immunology · 35
PDF
Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells
2005 · Frank Neumann, Claudia Wagner, et al. · Blood · 34
PDF
Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes
2004 · Frank Neumann, Claudia Wagner, et al. · Cancer Immunology Immunotherapy · 33
PDF
Immune Modulation by the Human Cytomegalovirus-Encoded Molecule UL18, a Mystery Yet to Be Solved
2008 · Claudia S Wagner, Hans-Gustaf Ljunggren, et al. · The Journal of Immunology · 27
Intracellular Regulation of Cross-Presentation during Dendritic Cell Maturation
2013 · Claudia S. Wagner, Jeff Grotzke, et al. · PLoS ONE · 22
PDF
Identification of an HLA‐DR‐restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM‐MEL‐40/SSX2
2004 · Frank Neumann, Claudia Wagner, et al. · International Journal of Cancer · 22
Structural Elements Underlying the High Binding Affinity of Human Cytomegalovirus UL18 to Leukocyte Immunoglobulin-like Receptor-1
2007 · Claudia S. Wagner, Alexander Rölle, et al. · Journal of Molecular Biology · 20
Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.
2003 · Claudia Wagner, Frank Neumann, et al. · PubMed · 20
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2023 · Apostolia M. Tsimberidou, Kerstin Guenther, et al. · Cancer Immunology Research · 16
PDF
Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma
2019 · Norbert Hilf, Sabrina Kuttruff-Coqui, et al. · Nature · 15
PDF
An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions
2023 · Stefan Krämer, Andreas Moritz, et al. · Scientific Reports · 10
PDF
SARS‐CoV‐2‐reactive T‐cell receptors isolated from convalescent COVID‐19 patients confer potent T‐cell effector function
2021 · Fabian Brunk, Andreas Moritz, et al. · European Journal of Immunology · 10
PDF
Author Correction: Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial
2025 · Martin Wermke, Dejka M. Araujo, et al. · Nature Medicine · 7
PDF
Effective Targeting of PRAME-Positive Tumors with Bispecific T Cell-Engaging Receptor (TCER®) Molecules
2019 · Sebastian Bunk, Martin Hofmann, et al. · Blood · 7
Works count: 108
Citation count: 2,240
H-index: 19
I10-index: 23
Year
Topic
Type